Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
The first five years will be a critical period for SCARDA, Japan’s newly set up command-tower squad for vaccine development, helmsman Michinari Hamaguchi tells Jiho. The unit’s initial focus will be on delivering homegrown mRNA jabs, which he hopes would…
To read the full story
Related Article
- SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
April 25, 2022
- SCARDA Now Up and Running: Will It Lead to a Recovery in Japan’s Ability to Develop Vaccines?
April 22, 2022
- SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
- Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
April 4, 2022
- AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
March 23, 2022
- Govt Council OKs Draft Policy to Strengthen Vaccine R&D, Establish SCARDA
March 1, 2022
- AMED to Set Up SCARDA in March to Spearhead Vaccine Development: President
January 12, 2022
- Japan Cabinet Hammers Out Strategy to Boost Vaccine Development
June 2, 2021
- Govt Mulls New AMED Organ to Lead Strategic Funding for Vaccine Development
May 26, 2021
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…